

## Antineutrophil cytoplasmic antibody-associated vasculitis in diffuse large B cell lymphoma


### Vasculitis asociada al anticuerpo citoplasma antineutrófilo en el linfoma difuso de células grandes B

Dear Editor:

A 70-year-old Japanese woman with a 57-year history of hepatitis C virus presented with nausea, abdominal pain, and renal dysfunction. Physical examination revealed splenomegaly. Blood examination revealed elevated levels of C reactive protein (2.7 mg/dL), serum creatinine (2.46 mg/dL), blood urea nitrogen (22 mg/dL), and uric acid (7.8 mg/dL). Test for myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) was positive (71.2 U/mL). Urinalysis showed proteinuria (0.56 g/gCr) and microhematuria (>100 red blood cells/high-power field). <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT) revealed FDG accumulation in the cervical, thoracic, and abdominal lymph nodes and spleen (Fig. 1A). Abdominal computed tomography

revealed splenomegaly with a low-density area (Fig. 1B). Renal biopsy specimen showed crescentic glomerulonephritis (Fig. 1C). Abdominal paraaortic lymph node biopsy revealed diffuse large B cell lymphoma (DLBCL). Based on these findings, the patient was diagnosed with ANCA-associated vasculitis (AAV) and DLBCL with suspected splenic DLBCL. Treatment with R-CHOP regimen was initiated, and her renal function improved. However, no remission was noted for the DLBCL. The patient died 4 months later.

Although malignant lymphomas are occasionally complicated by autoimmune diseases,<sup>1</sup> complication with AAV is notably rare.<sup>2</sup> There have been recent reports of ANCA-positive cases with B-cell lymphomas, especially intravascular lymphoma.<sup>3–6</sup> These cases, have included proven<sup>3,4</sup> or unproven<sup>5–7</sup> AAV. Moreover, an ANCA-positive case with splenic malignant lymphoma without proven AAV, as in this case,



**Fig. 1** – Findings of <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT), abdominal enhanced CT, and renal biopsy. (A) FDG-PET-CT shows FDG accumulation in the cervical, thoracic, and abdominal lymph nodes (yellow arrows) and spleen, indicating widespread lymphadenopathy and splenomegaly. (B) Abdominal enhanced CT shows splenomegaly (red arrow) with a low-density area. (C) Renal biopsy specimen reveals crescentic glomerulonephritis with fibrocellular crescent (arrow, Periodic acid-Schiff stain).

has been reported.<sup>7</sup> Like the above cases with intravascular lymphoma and/or embolic damage,<sup>5</sup> vascular damage caused by B cell lymphomas appeared to predispose the patient to ANCA. There have been reports of successful R-CHOP therapy, including rituximab, for both lymphoma and AAV.<sup>3-5</sup> Recently, the RAVE<sup>8</sup> and RITUXVAS<sup>9</sup> trials demonstrated that rituximab is effective for AAV, especially renal AAV. This is the first case of DLBCL-related AAV with biopsy-proven crescentic glomerulonephritis, and although R-CHOP did not provide lymphoma remission, renal function improved. Thus, rituximab could be effective for improving renal function in AAV. Clinicians should consider the possibility of AAV occurring as a complication in DLBCL.

Informed consent was obtained from the patient for the publication of this article.

#### BIBLIOGRAFÍA

1. Bilici A, Yapici HS, Ercan S, Seker M, Ustaalioglu BB, Salman T, et al. The prevalence and significance of autoantibodies in patients with non-Hodgkin's lymphoma: are they correlated with clinicopathological features? *J Buon*. 2012;17:502-7.
2. Hamidou MA, El Kouri D, Audrain M, Grolleau JY. Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. *Ann Rheum Dis*. 2001;60:293-5, <http://dx.doi.org/10.1136/ard.60.3.293>.
3. Tsuda M, Nakashima Y, Ikeda M, Shimada S, Nomura M, Matsushima T, et al. Intravascular large b-cell lymphoma complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis that was successfully treated with rituximab-containing chemotherapy. *J Clin Exp Hematop*. 2015;55:39-43.
4. Shinkawa Y, Hatachi S, Yagita M. Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis. *Mod Rheumatol*. 2019;29:195-7, <http://dx.doi.org/10.1080/14397595.2016.1205798>.
5. Sugiyama A, Kobayashi M, Daizo A, Suzuki M, Kawashima H, Kagami SI, et al. Diffuse cerebral vasoconstriction in a intravascular lymphoma patient with a high serum MPO-ANCA level. *Intern Med*. 2017;56:1715-8, <http://dx.doi.org/10.2169/internalmedicine.56.8051>.
6. Muto G, Takahashi Y, Yamashita H, Mimori A. A patient with intravascular lymphoma presenting with cerebral infarction and a high serum MPO-ANCA level. *Mod Rheumatol*. 2011;21:207-10, <http://dx.doi.org/10.1007/s10165-010-0361-z>.
7. Zuckerman KK, Leventhal L, Wynne C. Positive c-ANCA in a patient with lymphoma and without vasculitis. *J Clin Rheumatol*. 1997;3:279-81, <http://dx.doi.org/10.1097/00124743-199710000-00007>.
8. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010;363:221-32, <http://dx.doi.org/10.1056/NEJMoa0909905>.
9. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*. 2010;363:211-20, <http://dx.doi.org/10.1056/NEJMoa0909169>.

Taro Horino<sup>a,\*</sup>, Osamu Ichii<sup>b</sup>

<sup>a</sup> Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan

<sup>b</sup> Laboratory of Anatomy, Department of Basic Veterinary Sciences, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-Ku, Sapporo 060-0818, Japan

\* Corresponding author.

E-mail address: [horinott@yahoo.co.jp](mailto:horinott@yahoo.co.jp) (T. Horino).

<https://doi.org/10.1016/j.nefro.2020.04.017>

0211-6995/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de GKD-EPI

### Rivaroxaban Inappropriate Dosage Predictor Factors Using The Ckd-Epi Equation

Sr. Director:

Rivaroxabán está aprobado para la prevención del ictus y de la embolia sistémica en pacientes adultos con fibrilación auricular no valvular (FANV), con uno o más factores de riesgo. Para su dosificación se recomienda emplear la ecuación de Cockcroft-Gault (CG)<sup>1</sup>. Sin embargo, la ecuación *Chronic Kidney Disease Epidemiology Collaboration* (CKD-EPI) es el método

de elección para la determinación de la función renal y es la que proporciona la mayoría de los laboratorios de España<sup>2</sup>. Existen discrepancias entre los valores calculados entre ambas ecuaciones que pueden ocasionar errores en las dosis prescritas de rivaroxabán<sup>3,4</sup>. La prescripción de dosis inadecuadas se relaciona con un pronóstico cardiovascular adverso<sup>5</sup>. El objetivo de nuestro estudio es identificar a grupos de pacientes en los que puedan emplearse indistintamente las ecuaciones CKD-EPI y CG con bajo riesgo de prescripción errónea.